Skip to main content
Smart Investors Daily
SR

NASDAQ · SRZN

Surrozen, Inc.

Healthcare · Biotechnology

$24.01

Down-$1.20 (-5.00%)

Updated Aug 28, 2026, 2:11 PM

SID Score

5.8/10

Composite research score

Smart Money

Institutional and insider signal

Market cap
201.6M
P/E ratio
-12.03
Dividend yield
0.00%
52-week range
$10.73 – $35.00
Volume
340.75K
Avg. volume
63.79K

Price performance

SRZN price history

1M range · 21 trading sessions · Daily adjusted prices

SRZN closed at $24.01 after 21 trading sessions, up 15.27% for the selected period.

Last close
$24.01
Period change
+15.27%
Period low
$20.83
Period high
$25.62
Daily close
View OHLC price history
SRZN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 27, 2026$23.69$24.87$23.03$24.01340.75K
Aug 26, 2026$23.52$24.16$23.19$23.71128.75K
Aug 25, 2026$23.97$25.01$23.29$23.36218.97K
Aug 24, 2026$23.81$24.33$22.80$23.97163.64K
Aug 21, 2026$23.73$25.01$23.49$23.99149.72K
Aug 20, 2026$24.46$24.46$23.085$23.50135.33K
Aug 19, 2026$24.44$24.50$23.77$24.01122.46K
Aug 18, 2026$23.50$24.69$23.43$24.00148.58K
Aug 17, 2026$23.85$24.96$23.25$23.78163.51K
Aug 14, 2026$23.84$24.95$22.84$23.96212.87K
Aug 13, 2026$24.28$24.91$23.48$23.73432.92K
Aug 12, 2026$25.50$25.80$23.95$24.19271.49K
Aug 11, 2026$25.64$25.64$24.7201$25.05141.97K
Aug 10, 2026$25.60$26.27$24.88$25.09134.09K
Aug 7, 2026$24.84$27.32$22.30$25.62371.2K
Aug 6, 2026$21.74$22.40$21.15$21.64211.72K
Aug 5, 2026$21.65$22.55$20.73$21.95333.45K
Aug 4, 2026$22.12$22.95$20.745$22.00274.85K
Aug 3, 2026$22.45$23.12$21.355$21.78230.41K
Jul 31, 2026$21.00$22.58$20.75$22.21304.18K
Jul 30, 2026$19.25$21.53$19.055$20.831.07M

Latest SRZN news

The latest Smart Investors Daily articles mentioning SRZN.

SRZN research

Overview

Company profile and research snapshot.

Company profile

Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$38.50
Implied upside
Analysts
8
SRZN recent ratings
DateFirmRatingTarget
Aug 20, 2026William BlairOutperform
Aug 10, 2026HC Wainwright & Co.Buy
May 7, 2026HC Wainwright & Co.Buy
Apr 21, 2026TD CowenBuy
Mar 24, 2026HC Wainwright & Co.Buy
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 25, 2025

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. 37th Annual Piper Sandler Healthcare Conference on December 2, 2025Surrozen Fireside Discussion at 6:30 AM Pacific Time/9:30 AM Eastern T

globenewswire.com · Nov 25, 2025

Surrozen to Present at Upcoming Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.